Literature DB >> 28586522

Is sweat chloride predictive of severity of cystic fibrosis lung disease assessed by chest computed tomography?

Daan Caudri1,2, David Zitter1,3, Inez Bronsveld4, Harm Tiddens1,3.   

Abstract

BACKGROUND: Cystic Fibrosis (CF) lung disease is characterized by a marked heterogeneity. Sweat chloride-level is a functional marker of the CF Transmembrane Regulator (CFTR) protein and could be an important predictor of later disease severity.
METHODS: In this retrospective analysis children from the Rotterdam CF clinic with available sweat chloride level at diagnosis and at least one routine spirometry-controlled volumetric chest CT scan in follow-up were included. CT scans were scored using the CF-CT scoring system (% of maximum). Associations between sweat chloride-levels and CF-CT scores were calculated using linear regression models, adjusting for age at sweat test and age at follow-up. Because structural lung damage develops over the course of many years, effect modification by the age at follow-up CT-scan was tested for by age-stratification.
RESULTS: In 59 children (30 male) sweat chloride was measured at diagnosis (median age 0.5 years, range 0-13) and later chest CT performed (median age 14 years, range 6-18). Sweat chloride was associated with significantly higher CT-CT total score, bronchiectasis score, and mucus plugging score. Stratification for age at follow-up in tertiles showed this association remained only in the oldest age group (range 15-18 years). In that subgroup associations were found with all but one of the CF-CT subscores, as well as with all tested lung functions parameters.
CONCLUSION: Sweat chloride-level is a significant predictor of CF lung disease severity as determined by chest CT and lung function. This association could only be demonstrated in children with follow-up to age 15 years and above.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CFTR; biostatistics; bronchiectasis & primary ciliary dyskinesia; epidemiology; evidence-based medicine & outcomes; imaging; residual function

Mesh:

Substances:

Year:  2017        PMID: 28586522     DOI: 10.1002/ppul.23739

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  4 in total

1.  Thirty Years of Sweat Chloride Testing at One Referral Center.

Authors:  Alethéa Guimarães Faria; Fernando Augusto Lima Marson; Carla Cristina Souza Gomez; Maria de Fátima Servidoni; Antônio Fernando Ribeiro; José Dirceu Ribeiro
Journal:  Front Pediatr       Date:  2017-10-26       Impact factor: 3.418

2.  CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.

Authors:  Xi Zhang; Camille M Moore; Laura D Harmacek; Joanne Domenico; Vittobai Rashika Rangaraj; Justin E Ideozu; Jennifer R Knapp; Katherine J Woods; Stephanie Jump; Shuang Jia; Jeremy W Prokop; Russell Bowler; Martin J Hessner; Erwin W Gelfand; Hara Levy
Journal:  JCI Insight       Date:  2022-03-22

3.  Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.

Authors:  J S Guimbellot; A Baines; A Paynter; S L Heltshe; J VanDalfsen; M Jain; S M Rowe; S D Sagel
Journal:  J Cyst Fibros       Date:  2020-11-25       Impact factor: 5.482

4.  Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study.

Authors:  Harm A W M Tiddens; Eleni-Rosalina Andrinopoulou; Joe McIntosh; J Stuart Elborn; Eitan Kerem; Nynke Bouma; Jochem Bosch; Mariette Kemner-van de Corput
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.